Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab +/- Temozolomide in Advanced Melanoma
NCT04884997Phase 2Unknown
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Mar 2021
- Primary completion
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in Malignant Melanoma (MM), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Status: unknown.
02
Drugs
toripalimab
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT04884997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04884997.